Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2012 | 02:00pm CET

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
02:03pDJHSBC : to Buy Back More Shares After Net Loss Widens--3rd Update
02:03p DILLARD : misses 4Q profit forecasts
02:03p NAVISTAR INTERNATIONAL CORP : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
02:03p WESTINGHOUSE AIR BRAKE TECHNOLOGIES : Wabtec misses Street 4Q forecasts
02:03pDJCSX : Chief to Retire as Hunter Harrison Vies for Position
02:03p WIRELESS TELECOM GROUP INC : Regulation FD Disclosure (form 8-K)
02:03p Caribbean well positioned to capitalize on Internet growth, says Internet Society report
02:03p Switch and Play with Nintendo Switch in Unexpected Places across the U.S.
02:03p NAWBO National Women's Business Conference To Bring Elizabeth Gilbert And Gayle Lemmon To Minneapolis
02:03p CASTLIGHT HEALTH INC : Castlight Health, Inc. Recent Acquisition and Q4 Earnings Analysis
Latest news
Advertisement
Hot News 
-8.07%JOHN WOOD : posts 62 percent fall in FY profit, shares fall
-6.88%HSBC : Plans Further Buyback After 4th-Quarter Net Loss Widens to $4.23 Billion
2.26%Rosneft becomes first oil major to pre-finance Kurdish crude
1.39%TOTAL : Iran will finalise contract with Total within two months - minister
0.93%BAYER : Investors Upbeat on Takeover -- WSJ
Most Read News
06:29a Writedowns and tough outlook take their toll on HSBC
02/20 HSBC : Annual Results 2016 media release (30-page PDF 307KB)
04:12a BHP Billiton boosts payout on commodities surge
06:13a GENERAL MOTORS : PSA says will honour existing Opel labour agreements
02:17a TOP NEWS : Anglo American Beats Expectations, Commits To Dividend
Most recommended articles
07:58a VERIZON, YAHOO AGREE TO CUT DEAL PRICE BY AS MUCH AS $350 MILLION : Wsj
07:54a WAL MART STORES : Mart's quarterly comparable sales beat estimates
07:48a MEDTRONIC : quarterly revenue, profit beat estimates
07:45a ROYAL BANK OF SCOTLAND : Britain risks EU clash over RBS bailout terms
07:32aDJBAIDU : Raises $1.53 Billion for Video-Streaming Site iQiyi.com -- Update